GEP20257840B - Tyk2 pseudokinase ligands - Google Patents
Tyk2 pseudokinase ligandsInfo
- Publication number
- GEP20257840B GEP20257840B GEAP202015969A GEAP2020015969A GEP20257840B GE P20257840 B GEP20257840 B GE P20257840B GE AP202015969 A GEAP202015969 A GE AP202015969A GE AP2020015969 A GEAP2020015969 A GE AP2020015969A GE P20257840 B GEP20257840 B GE P20257840B
- Authority
- GE
- Georgia
- Prior art keywords
- ligands
- tyk2 pseudokinase
- tyk2
- pseudokinase ligands
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US202063046514P | 2020-06-30 | 2020-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20257840B true GEP20257840B (en) | 2025-12-25 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202015969A GEP20257840B (en) | 2019-11-08 | 2020-11-05 | Tyk2 pseudokinase ligands |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11753411B2 (enExample) |
| EP (1) | EP4054581A4 (enExample) |
| JP (1) | JP7635228B2 (enExample) |
| KR (1) | KR102938141B1 (enExample) |
| CN (1) | CN114929226B (enExample) |
| AU (1) | AU2020378345A1 (enExample) |
| BR (1) | BR112022008821A2 (enExample) |
| CA (1) | CA3160637A1 (enExample) |
| CL (1) | CL2022001178A1 (enExample) |
| CO (1) | CO2022007814A2 (enExample) |
| GE (1) | GEP20257840B (enExample) |
| IL (1) | IL292785B2 (enExample) |
| MX (1) | MX2022005563A (enExample) |
| PH (1) | PH12022551105A1 (enExample) |
| TW (1) | TWI882032B (enExample) |
| UA (1) | UA129894C2 (enExample) |
| WO (1) | WO2021092246A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2022519696A (ja) * | 2019-02-07 | 2022-03-24 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| CA3132632A1 (en) * | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| WO2024011136A1 (en) * | 2022-07-06 | 2024-01-11 | Ventyx Biosciences, Inc. | Crystalline forms of a tyk2 inhibitor |
| WO2024151992A1 (en) * | 2023-01-13 | 2024-07-18 | Ventyx Biosciences, Inc. | Preparation of a tyk2 inhibitor |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7557110B2 (en) | 2003-02-28 | 2009-07-07 | Teijin Pharma Limited | Pyrazolo[1,5-A] pyrimidine derivatives |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| TW202515876A (zh) | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| SI3658557T1 (sl) * | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| JP2022519696A (ja) | 2019-02-07 | 2022-03-24 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
| CA3132632A1 (en) | 2019-03-11 | 2020-09-17 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| JP7635228B2 (ja) | 2019-11-08 | 2025-02-25 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２偽キナーゼリガンド |
-
2020
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
- 2020-11-05 GE GEAP202015969A patent/GEP20257840B/en unknown
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 EP EP20884019.9A patent/EP4054581A4/en active Pending
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 AU AU2020378345A patent/AU2020378345A1/en active Pending
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
- 2020-11-05 KR KR1020227018394A patent/KR102938141B1/ko active Active
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022553841A (ja) | 2022-12-26 |
| CO2022007814A2 (es) | 2022-09-09 |
| CA3160637A1 (en) | 2021-05-14 |
| BR112022008821A2 (pt) | 2022-08-23 |
| CL2022001178A1 (es) | 2023-02-03 |
| JP7635228B2 (ja) | 2025-02-25 |
| US20230348478A1 (en) | 2023-11-02 |
| KR102938141B1 (ko) | 2026-03-11 |
| KR20220107194A (ko) | 2022-08-02 |
| AU2020378345A1 (en) | 2022-06-02 |
| TW202128698A (zh) | 2021-08-01 |
| WO2021092246A1 (en) | 2021-05-14 |
| US20210139486A1 (en) | 2021-05-13 |
| TWI882032B (zh) | 2025-05-01 |
| MX2022005563A (es) | 2022-08-19 |
| CN114929226B (zh) | 2024-09-27 |
| UA129894C2 (uk) | 2025-09-03 |
| IL292785A (en) | 2022-07-01 |
| US11753411B2 (en) | 2023-09-12 |
| IL292785B2 (en) | 2025-09-01 |
| EP4054581A1 (en) | 2022-09-14 |
| CN114929226A (zh) | 2022-08-19 |
| IL292785B1 (en) | 2025-05-01 |
| PH12022551105A1 (en) | 2023-11-20 |
| EP4054581A4 (en) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20257840B (en) | Tyk2 pseudokinase ligands | |
| MX2025003080A (es) | Conjugados de il-15, y sus usos | |
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MX2020002869A (es) | Compuestos de pirazolopirimidinona y usos de los mismos. | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| MX2025008493A (es) | Agentes de union a fibroblastos y uso de estos | |
| MX2021005348A (es) | Compuestos de piridazinonas y usos de los mismos. | |
| PH12022500003A1 (en) | Il-2 conjugates and methods of use to treat autoimmune diseases | |
| MX2020001187A (es) | Composiciones y métodos para la administración de virus adenoasociados. | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2019001920A (es) | Arn la terapia contra el cancer. | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| GEP20247585B (en) | Furoindazole derivatives | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| MY207469A (en) | Therapeutic compounds | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MX2019002284A (es) | Sistemas de deposito que comprenden acetato de glatiramer. | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. |